AMPH Earnings & Financial Statements
Amphastar Pharmaceuticals, Inc.
$26.08
+$0.03(+0.12%)
71
Overall
80
Value
66
Tech
68
Quality
Market Cap
$1.11B
Volume
364.65K
52W Range
$16.65 - $29.52
Target Price
$22.50
AMPH earnings and financial statements: Amphastar Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
AMPH Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $719.89M | $731.97M | $644.39M | $498.99M | $437.77M |
| Cost of revenue | $363.83M | $358.11M | $293.27M | $250.13M | $238.03M |
| Operating income | $140.40M | $205.42M | $196.99M | $107.50M | $69.89M |
| EBITDA | $215.61M | $282.72M | $249.71M | $145.44M | $111.57M |
| Net income | $98.09M | $159.52M | $137.54M | $91.39M | $62.12M |
| EPS (diluted) | $2.03 | $3.06 | $2.60 | $1.74 | $1.25 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.63B | $1.58B | $1.51B | $741.99M | $671.53M |
| Total liabilities | $840.49M | $845.17M | $873.49M | $213.33M | $226.01M |
| Shareholders’ equity | $788.80M | $732.30M | $639.42M | $528.66M | $445.52M |
| Cash and equivalents | $170.18M | $151.61M | $144.30M | $156.10M | $126.35M |
| Long-term debt | $646.43M | $643.51M | $619.30M | $96.53M | $99.48M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $156.12M | $213.39M | $183.50M | $89.18M | $97.99M |
| Capital expenditure | -$37.13M | -$41.04M | -$38.17M | -$24.03M | -$27.46M |
| Free cash flow | $118.98M | $172.34M | $145.34M | $65.15M | $70.54M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AMPH | $26.08 | +0.1% | 364.65K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Amphastar Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW